Literature DB >> 23242358

Parkinson disease psychosis: Update.

J H Friedman1.   

Abstract

Psychotic symptoms are common in drug treated patients with Parkinson's disease (PD). Visual hallucinations occur in about 30% and delusions, typically paranoid in nature, occur in about 5%. These problems, particularly the delusions, cause great distress for patient and caregivers, and are among the most important precipitants for nursing home placement. Psychotic symptoms carry a poor prognosis. They often herald dementia, and are associated with increased mortality. These symptoms often abate with medication reductions, but this may not be tolerated due to worsened motor function. Only clozapine has level A evidence to support its use in PD patients with psychosis (PDP), whether demented or not. While quetiapine has been recommended by the American Academy of Neurology for "consideration," double blind placebo controlled trials have demonstrated safety but not efficacy. Other antipsychotic drugs have been reported to worsen motor function and data on the effectiveness of cholinesterase inhibitors is limited. PDP remains a serious problem with limited treatment options.

Entities:  

Keywords:  Parkinson's disease psychosis; atypical antipsychotic drugs; delusions; hallucinations; neuroleptics; paranoia; parkinsonism

Mesh:

Substances:

Year:  2013        PMID: 23242358      PMCID: PMC5214983          DOI: 10.3233/BEN-129016

Source DB:  PubMed          Journal:  Behav Neurol        ISSN: 0953-4180            Impact factor:   3.342


  30 in total

1.  Associations of specific psychiatric disorders with isolated focal dystonia, and monogenic and idiopathic Parkinson's disease.

Authors:  Susanne Steinlechner; Johann Hagenah; Hans-Jürgen Rumpf; Christian Meyer; Ulrich John; Tobias Bäumer; Norbert Brüggemann; Meike Kasten; Alexander Münchau; Christine Klein; Rebekka Lencer
Journal:  J Neurol       Date:  2017-04-11       Impact factor: 4.849

2.  The differential actions of clozapine and other antipsychotic drugs on the translocation of dopamine D2 receptors to the cell surface.

Authors:  Joseph M Schrader; Craig M Irving; J Christopher Octeau; Joseph A Christian; Timothy J Aballo; Dean J Kareemo; Joseph Conti; Jodi L Camberg; J Robert Lane; Jonathan A Javitch; Abraham Kovoor
Journal:  J Biol Chem       Date:  2019-01-22       Impact factor: 5.157

3.  Drug Safety Analysis in a Real-Life Cohort of Parkinson's Disease Patients with Polypharmacy.

Authors:  Saskia Müller-Rebstein; Claudia Trenkwalder; Jens Ebentheuer; Wolfgang H Oertel; Carsten Culmsee; Günter U Höglinger
Journal:  CNS Drugs       Date:  2017-12       Impact factor: 5.749

4.  The effect of mirtazapine on dopaminergic psychosis and dyskinesia in the parkinsonian marmoset.

Authors:  Adjia Hamadjida; Stephen G Nuara; Nicolas Veyres; Imane Frouni; Cynthia Kwan; Lamia Sid-Otmane; Mery-Jane Harraka; Jim C Gourdon; Philippe Huot
Journal:  Psychopharmacology (Berl)       Date:  2017-01-27       Impact factor: 4.530

Review 5.  Psychosis in Parkinson Disease: A Review of Etiology, Phenomenology, and Management.

Authors:  Niyatee Samudra; Neepa Patel; Kyle B Womack; Pravin Khemani; Shilpa Chitnis
Journal:  Drugs Aging       Date:  2016-12       Impact factor: 3.923

Review 6.  Treatment of cognitive, psychiatric, and affective disorders associated with Parkinson's disease.

Authors:  Barbara Connolly; Susan H Fox
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 7.  Current Understanding of Psychosis in Parkinson's Disease.

Authors:  Oluwadamilola O Ojo; Hubert H Fernandez
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

8.  Anticholinergic burden in Parkinson's disease inpatients.

Authors:  Unax Lertxundi; Arantxazu Isla; Maria Angeles Solinis; Saioa Domingo-Echaburu; Rafael Hernandez; Javier Peral-Aguirregoitia; Juan Medrano
Journal:  Eur J Clin Pharmacol       Date:  2015-08-09       Impact factor: 2.953

Review 9.  Management of psychiatric disorders in Parkinson's disease : Neurotherapeutics - Movement Disorders Therapeutics.

Authors:  Daniel Weintraub
Journal:  Neurotherapeutics       Date:  2020-10       Impact factor: 7.620

Review 10.  Psychosis in Parkinson's Disease: Epidemiology, Pathophysiology, and Management.

Authors:  Anna Chang; Susan H Fox
Journal:  Drugs       Date:  2016-07       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.